Abstract 263P
Background
Primary Central Nervous System Lymphoma (PCNSL) is a rare type of non-Hodgkin’s lymphoma that tends to occur in the elderly and immunocompromised patients. The mainstay of treatment is that of high-dose methotrexate-based chemotherapy. Studies suggest that radiological response to high-dose methotrexate-based chemotherapy correlates with an improvement in neurocognitive ability that remains stable on follow-up. However, no studies involving patients with extremely poor neurological status prior to the commencement of chemotherapy have been reported, and the neurological prognosis of this group of patients remains unknown.
Methods
We describe 3 patients with biopsy-proven PCNSL that had comatose neurological states (Glasgow Coma Scale, GCS of 3-5) as a result of disease progression prior to treatment. The patients all experienced a drop in GCS in the short time frame between initial presentation and the start of treatment ranging from 12 days to 6 months.
Results
Case 1 initially presented with lethargy, drowsiness and behavioural change, with disease foci in a periventricular distribution. Case 2 presented with diplopia and poor visual acuity, as a result of disease affecting the optic chiasma and brainstem. Finally, case 3 had unsteady gait, memory impairment and slow speech at diagnosis, with disease over periventricular regions involving the corpus callosum and corona radiata. All were treated with high-dose methotrexate-based chemotherapy. However, although excellent radiological responses to treatment were achieved, no meaningful neurological or cognitive recovery was documented.
Conclusions
PCNSL patients with a baseline comatose state have poor neurological prognosis even if there is excellent tumour response to chemotherapy. As it is an aggressive disease with an unpredictable clinical course, rapid detection and prompt treatment is crucial in this disease entity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session